-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lipid nanoparticles (LNPs) are currently two widely used delivery vehicles for mRNA COVID-19 vaccines
It has been shown that by changing the structure of the lipid molecules that make up LNPs, the specificity of their targeting to tissues can be altered
Further research found that when lung-targeting LNPs enter the bloodstream, they cause specific plasma proteins to attach to the surface of the LNPs, giving them the ability to target lung tissue
To further verify the role of this LNP, the researchers used it to deliver mRNA encoding the normal Tsc2 gene to mice with lymphangioleiomyomatosis due to an inactivating mutation in the Tsc2 gene
References:
[1] Targeting gene therapy directly into the lungs.
[2] Qiu et al.
(Original abridged)